The three most common retinal diseases—age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)—can all be effectively treated with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibodies [4–6]. This evidence concerns the gene VEGFA and age-related macular degeneration.